Richter has announced that they have entered into an exclusive distribution agreement to market and sell Orexo´s patented Rapinyl™ drug (for management of breakthrough cancer pain) in CIS, Bulgaria and Romania. Richter has signed last July an agreement with ProStrakan (holding the distribution rights for Rapinyl™ for the EU market) to market the same drug within CEE markets.
Our view: We see this news mildly positive, as the geographical extension of the license-in agreement enables Richter leverage out its strong market position in the CEE and CIS regions.